Show simple item record

dc.contributor.authorGilleece, Maria Hen
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorGhosh, Anna Ken
dc.contributor.authorHeyworth, Clare Men
dc.contributor.authorBonnem, Een
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorStern, Peter Len
dc.contributor.authorDexter, T Michaelen
dc.date.accessioned2010-08-16T14:27:48Z
dc.date.available2010-08-16T14:27:48Z
dc.date.issued1992-07
dc.identifier.citationRecombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial. 1992, 66 (1):204-10 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid1637669
dc.identifier.urihttp://hdl.handle.net/10541/109648
dc.description.abstractRecombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative disease should be selected for Phase II trials.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshBone Marrow
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunoglobulin G
dc.subject.meshInjections, Subcutaneous
dc.subject.meshInterleukin-4
dc.subject.meshLeukocyte Count
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshPlatelet Count
dc.subject.meshReceptors, Interleukin-4
dc.subject.meshReceptors, Mitogen
dc.subject.meshRecombinant Proteins
dc.titleRecombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign, Department of Experimental Haematology, Christie Hospital NHS Trust, Manchester, U.K.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractRecombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative disease should be selected for Phase II trials.


This item appears in the following Collection(s)

Show simple item record